key: cord-0272159-hvihj9b1 authors: Christensen, P. A.; Olsen, R. J.; Long, S. W.; Snehal, R.; Davis, J. J.; Ojeda Saavedra, M.; Reppond, K.; Shyer, M. N.; Cambric, J.; Gadd, R.; Thakur, R. M.; Batajoo, A.; Mangham, R.; Pena, S.; Trinh, T.; Kinskey, J. C.; Williams, G.; Olson, R.; Golihar, J.; Musser, J. M. title: Early signals of significantly increased vaccine breakthrough, decreased hospitalization rates, and less severe disease in patients with COVID-19 caused by the Omicron variant of SARS-CoV-2 in Houston, Texas date: 2022-01-01 journal: nan DOI: 10.1101/2021.12.30.21268560 sha: 5b66bf4e9f24b69dd72850689d464c155335bd61 doc_id: 272159 cord_uid: hvihj9b1 Genetic variants of SARS-CoV-2 continue to dramatically alter the landscape of the COVID-19 pandemic. The recently described variant of concern designated Omicron (B.1.1.529) has rapidly spread worldwide and is now responsible for the majority of COVID-19 cases in many countries. Because Omicron was recognized very recently, many knowledge gaps exist about its epidemiology and clinical severity and disease course. A comprehensive genome sequencing study of SARS-CoV-2 in the Houston Methodist healthcare system identified 862 symptomatic patients with infections caused by Omicron from late November 2021 through December 18, 2021. Omicron very rapidly increased in only three weeks to cause 90% of all new COVID-19 cases. Compared to patients infected with either Alpha or Delta variants in our healthcare system, Omicron patients were significantly younger, had significantly increased vaccine breakthrough rates, and were significantly less likely to be hospitalized. Omicron patients required less intense respiratory support and had a shorter length of hospital stay, consistent with decreased disease severity. Although the number of Omicron patients we studied is relatively small, in the aggregate the data document the unusually rapid spread and increased occurrence of COVID-19 caused by the Omicron variant in metropolitan Houston, and provide information about disease character. including but not limited to increased vaccination uptake, population immunity, and 109 patient demographics such as younger age. The extent to which our findings translate 110 to other cities and other patient populations, including children, is unknown. Our study 111 was not designed to address possible intrinsic differences in virulence of Omicron 112 compared to Alpha, Delta, and other VOCs. We believe this topic remains an open 113 question that warrants further investigation. with the Omicron VOC and Alpha and Delta VOCs, all patients documented to be 130 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2021 infected with these variants in the Houston Methodist system were studied. The study 131 included 36,164 unique patients identified in this time frame for whom we had SARS-132 CoV-2 & Influenza A/B Assay using the Roche Liat system, the SARS-CoV-2 Assay 146 using the Hologic Panther instrument, the Aptima SARS-CoV-2 Assay using the Hologic 147 Panther Fusion system, the Cobas SARS-CoV-2 test using the Roche 6800 system, 148 and the SARS-CoV-2 assay using Abbott Alinity m instruments. Virtually all tests were 149 performed on material obtained from nasopharyngeal swabs immersed in universal 150 transport media (UTM); oropharyngeal or nasal swabs, bronchoalveolar lavage fluid, or 151 sputum treated with dithiothreitol (DTT) were sometimes used. Standardized specimen 152 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 (https://cov-lineages.org/resources/pangolin.html, last accessed December 12, 2021). 176 Genome data used in this study have been deposited to GISAID www.gisaid.org. A booster vaccination breakthrough case was defined as a PCR-positive sample from a 197 patient obtained greater than 14 days after receiving a third vaccine dose. For some 198 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 cases, manual chart review was conducted to resolve discrepancies or clarify 199 ambiguities. There is a considerable lack of detailed information about patients in the United States 240 and elsewhere with COVID-19 caused by the Omicron VOC. We compared available 241 metadata for all Houston Methodist patients infected with Omicron, Alpha, and Delta 242 VOCs ( Table 1, Table 2 ). The populations differed significantly in many characteristics, 243 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 including median age, hospital admission rates, maximum respiratory support, rate of 244 vaccine breakthrough, and median length of stay ( Table 1, Table 2) . 245 Patients infected with Omicron were significantly younger than Alpha and Delta 246 patients ( Table 1, Table 2 ). Importantly, Omicron patients were hospitalized significantly 247 less frequently than patients infected with either the Alpha or Delta variants, and had a 248 significantly shorter median hospital length of stay ( breakthrough cases, it has been reported that this variant has reduced sensitivity to 265 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 antibody neutralization in vitro, likely in large part due to the extensive number of amino 266 acid and other structural changes occurring in Omicron spike protein [10] [11] [12] [13] [14] [15] [16] [17] [18] [19] [20] [21] [22] [23] [24] [25] [26] [27] [28] [29] . (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. additional mutations unique to it (https://github.com/cov-lineages/pango-303 designation/issues/361; last accessed December 30, 2021). One important difference is 304 that sublineage BA.2 lacks the spike protein deletion at amino acid 69/70 which means 305 that it will not be detected by the SGTF assay. We inspected all full genome sequences 306 present in our large database and this sublineage was not present. This includes all 307 specimens taken from symptomatic patients or asymptomatic individuals. Thus, it is 308 likely that routine use of an SGTF assay in our population will identify patients infected 309 with Omicron. 310 311 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 In this work, we describe information relevant to the surging Omicron wave in 314 metropolitan Houston. In three weeks, Omicron was first identified in our population and 315 rapidly increased to cause 90% of all new COVID-19 cases, with an estimated case 316 doubling time of 2.2 days. The study was based on genome sequence analysis of 862 317 Omicron samples taken from socioeconomically, geographically, and ethnically diverse 318 symptomatic patients. Several key findings were made, including (i) the Omicron VOC 319 rapidly increased as a cause of COVID-19 and spread throughout the metroplex in an 320 unusually short period of time, far faster than any other SARS-CoV-2 variant; (ii) 321 Omicron caused significantly more vaccine breakthrough cases than the Alpha or Delta 322 VOCs; (iii) Omicron patients were significantly younger than Alpha or Delta patients; (iv) 323 significantly fewer Omicron patients required hospitalization compared to Alpha and 324 Delta patients; (v) the median length of stay for hospitalized Omicron patients was 325 significantly shorter than for Alpha and Delta patients, and consistent with this 326 observation, the maximum respiratory support required for Omicron patients was 327 significantly less than for Alpha or Delta patients. Our findings are largely consistent 328 with many aspects of Omicron data reported from the UK, South Africa, and Canada 7-9, 329 32, 33 and are consistent with animal infection model data suggesting that Omicron 330 causes less severe disease in mice and hamsters 34, 35 . This study was facilitated by a 331 comprehensive and integrated population genomics and epidemiology project 2-6 332 implemented at the end of February, 2020, when the initial COVID-19 case was 333 diagnosed in the Houston Methodist healthcare system. 334 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2021 Because we sequence the genome of approximately 90% of SARS-CoV-2 335 causing COVID-19 in our diverse Houston Methodist patient population, and have done 336 so for almost two years, this means we are continuously monitoring the composition of 337 this virus in a major US metroplex. This affords us the opportunity to rapidly assess 338 changes in SARS-CoV-2 population genomic structure in the fourth largest city in the 339 US. However, our study has several limitations. Although we sequenced the genomes 340 of SARS-CoV-2 causing 90% of all Houston Methodist COVID-19 cases in the study 341 period, this sample represents only approximately 5% of cases reported in the 342 metropolitan region. Our patient population will underrepresent some demographic 343 groups, for example homeless individuals and pediatric patients. The samples 344 sequenced in this study were obtained from symptomatic individuals, which means that 345 it is possible that we failed to identify Omicron subvariants or features preferentially 346 represented in asymptomatic individuals. 347 In the aggregate, our data add critical new information to features of Omicron 348 genomic epidemiology and patient characteristics in the US. Further, the present study 349 highlights the importance of analyzing SARS-CoV-2 genome data integrated with 350 patient metadata and stresses the need to continue to do this in near-real time as the 351 Omicron surge continues, the virus evolves, and new variants with potentially altered 352 fitness and biomedically relevant phenotypes are generated. Analyses of this type are 353 also important in the context of vaccine formulation and long COVID, an increasing 354 health and economic problem globally. Finally, the strategy we have used in this and 355 previous studies 2-6 are readily applicable to future infectious diseases problems that 356 warrant special attention. 357 All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org/10.1101 https://doi.org/10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 Chi-square Mechanical Ventilation 6 (4.5%) 720 (10.7%) 726 (10.6%) All rights reserved. No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted January 1, 2022. ; https://doi.org /10.1101 /10. /2021 Genomic characterization and 386 Epidemiology of an emerging SARS-CoV-2 variant in Delhi Molecular Architecture of Early Dissemination and Massive Second Wave of the 392 SARS-CoV-2 Virus in a Major Metropolitan Area Rapid, 394 widespread, and preferential increase of SARS-CoV-2 B.1.1.7 variant in Houston, TX, revealed by 395 8,857 genome sequences Trajectory of Growth of Severe Acute 399 Respiratory (SARS-CoV-2) Syndrome Coronavirus 2 Variants in Sequence 403 Analysis of 20,453 SARS-CoV-2 Genomes from the Houston Metropolitan Area Identifies the 404 Emergence and Widespread Distribution of Multiple Isolates of All Major Variants of Concern 409 Delta Variants of SARS-CoV-2 Cause Significantly Increased Vaccine Breakthrough COVID-19 410 Cases in Rapid epidemic expansion of the SARS-CoV-2 424 Omicron variant in southern Africa Rapid increase in Omicron infections in 428 England during Severity of 430 Omicron variant of concern and vaccine effectiveness against symptomatic disease: national 431 cohort with nested test negative design study in Scotland SARS-CoV-2 Omicron spike mediated immune escape, 435 infectivity and cell-cell fusion Neutralization and Stability of 438 SARS-CoV-2 Omicron Variant Diminished neutralization responses towards SARS-CoV Omicron VoC after mRNA or vector-based COVID-19 vaccinations Increased risk of 447 infection with SARS-CoV-2 Omicron compared to Delta in vaccinated and previously infected 448 individuals, the Netherlands mRNA-1273 and BNT162b2 mRNA vaccines have reduced neutralizing activity against the SARS-455 CoV-2 Omicron variant Neutralization 457 against Omicron SARS-CoV-2 from previous non-Omicron infection SARS-CoV-2 Omicron 460 variant escapes neutralization by vaccinated and convalescent sera and therapeutic monoclonal 461 antibodies Reduced 464 neutralisation of SARS-COV-2 Omicron-B.1.1.529 variant by post-immunisation serum Broadly neutralizing antibodies 472 overcome SARS-CoV-2 Omicron antigenic shift Striking Antibody Evasion Manifested by the Omicron Variant of SARS-CoV-476 2 Considerable escape of 481 SARS-CoV-2 variant Omicron to antibody neutralization Effectiveness of COVID-19 486 vaccines against the Omicron (B.1.1.529) variant of concern CoV-2 Omicron variant to booster-enhanced neutralization Sigal A: 495 SARS-CoV-2 Omicron has extensive but incomplete escape of Pfizer BNT162b2 elicited 496 neutralization and requires ACE2 for infection 1.1.529 escapes the majority of SARS-CoV-2 500 neutralizing antibodies of diverse epitopes Vaccine effectiveness against SARS-CoV-2 infection with 503 the Omicron or Delta variants following a two-dose or booster BNT162b2 or mRNA-1273 504 vaccination series: A Danish cohort study Omicron mutations enhance infectivity and reduce antibody neutralization of SARS-508 CoV-2 virus-like particles Variable loss of antibody potency against SARS-CoV-511 513 Neutralizing antibodies to SARS-CoV-2 Omicron variant after 3rd mRNA vaccination in health 514 care workers and elderly subjects and response to a single dose in previously infected adults 529 (Omicron) variant of concern SARS-CoV-523 2 spike L452R variant evades cellular immunity and increases infectivity The Impact of Mutations in SARS-CoV-2 Spike 527 on Viral Infectivity and Antigenicity Early estimates of SARS-CoV-2 Omicron 529 variant severity based on a matched cohort study Early assessment of the clinical severity of the 535 SARS-CoV-2 Omicron variant in South Africa 1.1.529 Variant leads to less severe disease than Pango B and Delta variants strains 539 in a mouse model of severe COVID-19 The omicron (B.1.1.529) SARS-CoV-2 variant of concern does 542 not readily infect Syrian hamsters No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity 4%) Fisher's exact test Odds Ratio Vaccine No vaccine 403 BMI: body mass index; CI: confidence interval; ECMO: extracorporeal membrane oxygenation; LOS: length of stay 577 No reuse allowed without permission. (which was not certified by peer review) is the author/funder, who has granted medRxiv a license to display the preprint in perpetuity. The copyright holder for this preprint this version posted